In early trading today, A-Shares continued to fluctuate slightly, major stock indexes rose and fell, the market holiday atmosphere was strong, and the trading was still flat.
On the disk, it is dominated by individual stock market. Salt lake lithium extraction, digital currency, Yuan universe, seed industry and other sectors are relatively active, while coal, cultivation diamond, water, food and beverage and other sectors lead the decline. The net inflow of funds going north was 1.917 billion yuan.
Kaifa pharmaceutical plunged more than 80%
Today is the first trading day after the Christmas holiday in the Hong Kong stock market, Kaifa pharmaceutical announced the progress of phase III clinical trial of covid-19 in the treatment of mild and moderate non hospitalized covid-19 patients. It said that according to the interim analysis data of 348 covid-19 patients, due to the small number of events, it did not reach statistical significance, The company plans to adjust the clinical trial scheme for patient recruitment. As soon as the news came out, Kaifa pharmaceutical opened 14.93% lower in the morning, then suddenly collapsed and fell 84.71%. In the blink of an eye, the wealth of nearly HK $15 billion disappeared.
Let’s take a look at the description of the company’s announcement.
As of December 23, 2021, the company has completed the patient recruitment of the phase III clinical trial according to the original scheme, of which more than 95% of the patients are from the United States. All patients in the interim analysis were from the United States, and the hospitalization rate in the United States was very low.
As the covid-19 epidemic is still aggravating, especially the emergence of Omicron mutant, it highlights the demand for covid-19 therapeutic drugs. Research is very important for effective treatment of mutant virus. The company believes that prochloramide can become an important tool against covid-19, and will continue to strengthen this registered clinical trial. The company will provide the final data analysis results of the non inpatient clinical trial in the future.
The phase III clinical trial for non hospitalized patients is a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of prochloramide in non hospitalized mild and moderate patients with covid-19. In the interim analysis, 348 non hospitalized male and female patients with one or more mild symptoms within 5 days were recruited. Patients were randomly assigned to prochloramide treatment group (receiving 200 mg prochloramide) or placebo control group, orally twice a day for 14 days. The recruited covid-19 patients did not exclude those who had been vaccinated with covid-19, nor did they exclude patients without risk factors. The treatment group or placebo control group received the same standard treatment. The primary endpoint of the clinical trial was the percentage of patients hospitalized (more than 24 hours) and died within 28 days.
At present, the company has conducted two phase III global multicenter clinical trials (nct04870606 and nct04869228) of prochloramide for non hospitalized covid-19 patients with mild and moderate diseases and one phase III global multicenter clinical trial (nct05009732) for hospitalized covid-19 patients with severe diseases in the United States, South America (including Brazil), Asia (including China) and the European Union, And obtained the emergency use authorization (EUA) for the treatment of hospitalized covid-19 patients in Paraguay.
It is not too much to describe the development of the pharmaceutical industry as “its prosperity is also vigorous and its death is also sudden”. Previously, benefiting from the outbreak of covid-19 epidemic, the development of pharmaceutical industry soared more than 10 times to more than HK $80 in only about five months from the end of 2020. After peaking at HK $89 in September this year, it fell rapidly and closed at HK $45.2 before Christmas. Today, the stock price plunged to a record low of HK $6.91.
The market generally believes that the phase III clinical trial of developing the pharmaceutical industry has failed according to the currently published results. However, the development of pharmaceutical industry is still optimistic about the prospect of prochloramide. Pioneer pharmaceutical stressed that the company believes that prochloramide can become an important tool against covid-19 and will continue to strengthen this registered clinical trial.
Professionals said that although the company intends to replace the more stringent clinical program to achieve the purpose of approval, it will not have new clinical results until at least half a year later. At the same time, it is worth noting that the company did not disclose detailed interim clinical data, so it is impossible to know exactly how the effect is.
two new shares broke on the first day
The new shares of Nanmo biology on the science and innovation board and oni electronics on the gem both broke.
the offering price of Nanmo biology is 84.62 yuan, with a P / E ratio of 201.59 times. At the opening of the morning, it fell 11.14% compared with the offering price, and then continued to fall, with a minimum of 70.66 yuan or 16.5%. If calculated at the lowest price, the investors who win each lot will lose nearly 7000 yuan.
According to the official website of Nanmo biology, its main business is related to genetically modified animal model products and technical services. It focuses on the field of model biology, specializes in the R & D, breeding, analysis and detection of genetically modified animal models, and is committed to providing comprehensive, convenient and professional model biotechnology services and model resources for global universities, scientific research institutes, hospitals and pharmaceutical enterprises. Focusing on model animals, the production and experimental base is 14000m2, and the SPF professional animal room can accommodate about 300000 mice. More than 300 kinds of prefabricated mouse models can be selected, and more than 3000 genetically modified mouse models have been established in total.
The company has established good cooperative relations with many scientific research teams of famous institutions such as Chinese Academy of Sciences, Fudan University, Shanghai Jiaotong University, Zhejiang University, Tsinghua University and Peking University, Ruijin Hospital, Zhongshan Hospital and Huashan Hospital, as well as well-known innovative drug R & D companies such as YaoMing biology, Xinda biology, Jiangsu Hengrui Medicine Co.Ltd(600276) , Baiji Shenzhou and Sino US Guanke.
The issue price of oney electronics is 66.18 yuan, with an issue price earnings ratio of 40.18 times. In the morning, oney electronics opened low by 1.78%, and then fluctuated sharply. First, it fell rapidly, falling to 54 yuan or 18.4%, and then rebounded sharply, once approaching the issue price. As of the noon closing, it closed at 58.9 yuan, down 11%. If calculated at the lowest price, the investor who wins each contract will lose 6090 yuan.
Oney electronics started its business with an external computer camera, focusing on the audio-visual data collection, transmission and processing of application scenarios such as smart home, smart travel and smart office. Its core products are intelligent audio-visual terminals such as computer / TV external camera, webcam, tachograph and Bluetooth headset. As a leading enterprise in the consumer Internet of things industry, oneI electronics has been deeply engaged in the field of intelligent audio-visual for more than ten years.
Previously, oney electronics developed rapidly. From 2018 to 2020, the operating revenue of oney Electronics was 295 million yuan, 528 million yuan and 1084 million yuan respectively; The net profit attributable to the parent company was 2.5933 million yuan, 48.7722 million yuan and 193 million yuan respectively. The compound growth rates of the company’s operating revenue and net profit attributable to the parent company reached 91.54% and 761.97% respectively. However, in 2021, the growth rate of oni electronics suddenly decreased. The operating revenue in the first three quarters was 718 million yuan, a year-on-year increase of only 3.31%, and the net profit decreased by 21.54%.
Plummeted 85%! What happened to the sudden collapse of tenfold pharmaceutical bull stocks in early trading?
The share price fell from HK $89 to less than HK $7. How to continue the “myth” of developing the pharmaceutical industry?
(E company)
